Accretion Nutraveda Ltd
Incorporated in 2021, Accretion Nutraveda is engaged in the manufacturing of Ayurvedic and Nutraceutical products in various dosage forms.[1]
- Market Cap ₹ 197 Cr.
- Current Price ₹ 272
- High / Low ₹ 300 / 150
- Stock P/E 38.8
- Book Value ₹ 49.0
- Dividend Yield 0.00 %
- ROCE 27.6 %
- ROE 24.8 %
- Face Value ₹ 10.0
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 35.0%
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Debtor days have increased from 60.3 to 88.1 days.
- Working capital days have increased from 157 days to 352 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE SME IPO
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| 2.89 | 5.01 | 16.00 | 33.60 | |
| 2.27 | 3.78 | 12.28 | 26.71 | |
| Operating Profit | 0.62 | 1.23 | 3.72 | 6.89 |
| OPM % | 21.45% | 24.55% | 23.25% | 20.51% |
| 0.17 | 0.19 | 0.05 | 0.11 | |
| Interest | 0.19 | 0.24 | 0.35 | 0.53 |
| Depreciation | 0.31 | 0.26 | 0.24 | 0.26 |
| Profit before tax | 0.29 | 0.92 | 3.18 | 6.21 |
| Tax % | 3.45% | 9.78% | 17.92% | 18.36% |
| 0.28 | 0.82 | 2.61 | 5.07 | |
| EPS in Rs | 7.78 | 22.78 | 53.59 | 7.00 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 127% |
| TTM: | 110% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 163% |
| TTM: | 94% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 35% |
| Last Year: | 25% |
Balance Sheet
Figures in Rs. Crores
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Equity Capital | 0.36 | 0.36 | 0.49 | 7.24 |
| Reserves | -0.10 | 0.72 | 4.86 | 28.23 |
| 1.97 | 2.17 | 3.86 | 4.23 | |
| 1.83 | 1.39 | 1.65 | 2.09 | |
| Total Liabilities | 4.06 | 4.64 | 10.86 | 41.79 |
| 1.49 | 1.28 | 2.02 | 1.66 | |
| CWIP | 0.00 | 0.10 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| 2.57 | 3.26 | 8.84 | 40.13 | |
| Total Assets | 4.06 | 4.64 | 10.86 | 41.79 |
Cash Flows
Figures in Rs. Crores
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| 0.68 | 0.23 | -2.21 | -23.92 | |
| -0.01 | -0.16 | -0.87 | -0.08 | |
| -0.63 | -0.04 | 2.98 | 25.27 | |
| Net Cash Flow | 0.04 | 0.03 | -0.10 | 1.26 |
| Free Cash Flow | 0.67 | 0.07 | -3.08 | -24.00 |
| CFO/OP | 110% | 27% | -45% | -331% |
Ratios
Figures in Rs. Crores
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Debtor Days | 101.04 | 18.21 | 74.60 | 88.10 |
| Inventory Days | 279.12 | 303.74 | 158.50 | 136.10 |
| Days Payable | 354.26 | 113.58 | 30.73 | 13.63 |
| Cash Conversion Cycle | 25.89 | 208.37 | 202.36 | 210.57 |
| Working Capital Days | 8.84 | 7.29 | 111.32 | 352.07 |
| ROCE % | 42.34% | 56.66% | 27.56% |
Insights
In beta| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Capacity Utilization - Capsules % |
|
||
| Capacity Utilization - External Preparations % |
|||
| Capacity Utilization - Oral Liquid % |
|||
| Capacity Utilization - Tablets % |
|||
| Customer Concentration (Top 10 Clients) % |
|||
| Fixed Asset Turnover Ratio x |
|||
| Installed Capacity - Capsules Nos |
|||
| Installed Capacity - External Preparations Nos |
|||
| Installed Capacity - Oral Liquid Nos |
|||
| Installed Capacity - Tablets Nos |
|||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
17h - FY26 audited results: revenue rose 110% to ₹33.6 crore, PAT up 102.8% to ₹5.07 crore.
-
Appointment Of Internal Auditors
8 May - FY26 audited results approved; two independent directors resigned and two appointed on 8 May 2026.
-
Appointment Of Secretarial Auditors
8 May - FY26 audited results approved; two independent directors resigned, two new independent directors appointed on 8 May 2026.
-
Announcement under Regulation 30 (LODR)-Change in Management
8 May - Audited FY26 profit rose to ₹506.83 lakh; two independent directors resigned, two appointed.
-
Announcement under Regulation 30 (LODR)-Change in Management
8 May - Board approved FY26 audited results; two independent directors resigned, and two new independent directors appointed on 8 May 2026.
Business Profile[1]
Accretion Nutraveda Limited is a healthcare-focused Ayurveda and Nutraceutical CDMO, manufacturing a wide range of Ayurvedic and nutraceutical products across multiple dosage forms for domestic clients, merchant exporters, and direct export customers.